Search
for
Sort by
Research 91–120 of 1000+
- Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
- No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study
- Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease
- Long-term Treatment with a 5-Alpha-Reductase Inhibitor AlleviatesDepression-like Behavior in Obese Male Rats
- Adverse effects of the 5-alpha-reductase inhibitor finasteride on Daphnia magna: Endocrine system and lipid metabolism disruption
- Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: a global propensity score matched retrospective cohort study
- Adverse Effects of the 5-Alpha-Reductase Inhibitor Finasteride on Daphnia Magna: Endocrine System and Lipid Metabolism Disruption
- 5 Alpha-Reductase Inhibitory Potential of Solanum nigrum Effective for Management of Alopecia
- pH STIMULUS-RESPONSIVE HYBRID NANOPARTICLES: A SYSTEM DESIGNED FOR FOLLICULAR DELIVERY OF BRAZILIAN PLANT-DERIVED 5-ALPHA-REDUCTASE ENZYME INHIBITORS
- Chronic Exposure with 5‐Alpha Reductase Inhibitor Ameliorates Anxiety and Depression‐like Behaviors By Reducing Systemic Oxidative Stress in D‐galactose‐Induced Aging Male Rats
- Chronic Exposure of 5‐Alpha Reductase Inhibitor in Young Male Rats Induces Not Only Metabolic Disturbance, But Also Depressive‐Like Behaviors as Similar with Obese Condition
- Litigation associated with 5-alpha-reductase-inhibitor use: A Canadian legal database review.
- 5-alpha reductase inhibitors use in prostatic disease and beyond
- Adverse Effects of 5-Alpha-Reductase Inhibitors: a narrative review
- 5-Alpha-Reductase Inhibitor Treatment for Frontal Fibrosing Alopecia:A Myth or Truth?
- MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
- MP85-05 SEXUAL DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE: INSIGHTS FROM THE REDUCE STUDY GROUP DATABASE
- 1153 ERECTILE HEMODYNAMICS ASSESSMENT IN MEN WITH PERSISTENT ERECTILE DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE
- (719) Signal Detection of Depression and Suicidality With the 5-Alpha Reductase Inhibitors: Evidence from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database
- Impact of 5-alpha Reductase Inhibitors on Male Reproductive Health: A Review of Finasteride and Dutasteride.
- Supplementary Material for: Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
- Supplementary Material for: Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
- An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications
- Comparative Efficacy of Minoxidil and 5‐Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta‐Analysis Study of Current Empirical Evidence
- 5-Alpha Reductase Inhibitors on Hypersexuality During the Manic Phase of Bipolar and Psychotic Patients; New Insight to a Well-Known Medicines
- Risk associated with the use of 5-alpha reductase inhibitors with minoxidil in treatment of male androgenetic alopecia – literature review
- 5-Alpha-Reductase Inhibitors in the Treatment of Male Androgenetic Alopecia: Clinical Experience
- Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors